<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2019//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_190101.dtd">
<PubmedArticleSet>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated">
      <PMID Version="1">33812977</PMID>
      <DateCompleted>
        <Year>2021</Year>
        <Month>06</Month>
        <Day>28</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2021</Year>
        <Month>06</Month>
        <Day>28</Day>
      </DateRevised>
      <Article PubModel="Print-Electronic">
        <Journal>
          <ISSN IssnType="Electronic">1873-7528</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>126</Volume>
            <PubDate>
              <Year>2021</Year>
              <Month>Jul</Month>
            </PubDate>
          </JournalIssue>
          <Title>Neuroscience and biobehavioral reviews</Title>
          <ISOAbbreviation>Neurosci Biobehav Rev</ISOAbbreviation>
        </Journal>
        <ArticleTitle>The effect of antipsychotics on the cognitive performance of individuals with psychotic disorders: Network meta-analyses of randomized controlled trials.</ArticleTitle>
        <Pagination>
          <StartPage>265</StartPage>
          <EndPage>275</EndPage>
          <MedlinePgn>265-275</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="doi" ValidYN="Y">10.1016/j.neubiorev.2021.03.028</ELocationID>
        <ELocationID EIdType="pii" ValidYN="Y">S0149-7634(21)00145-7</ELocationID>
        <Abstract>
          <AbstractText>Cognitive deficits are a core aspect of psychotic disorders; however, it is not clear to which extent different pharmacological treatments could distinctly impact these outcomes. Hence, we conducted a systematic review and ten network meta-analyses of randomized controlled trials to compare the effect of antipsychotics on cognitive performance of individuals with psychotic disorders. Fifty-four trials were included in the analyses, enrolling 5866 patients. Compared to other antipsychotics, amisulpride performed better on verbal learning; quetiapine on composite score, attention and verbal learning; lurasidone on composite score; olanzapine on composite score and most cognitive domains; perphenazine on composite score, executive function, working memory, and verbal learning; risperidone on executive function and verbal learning; sertindole on processing speed; and ziprasidone on composite score, working memory, and verbal learning. Oppositely, haloperidol performed poorer on all cognitive domains, occupying the last positions in all rankings; and clozapine performed poorer on composite score, executive function, verbal learning, and visuoconstruction. We hope that these results should be taken into account when assessing and treating individuals with psychosis.</AbstractText>
          <CopyrightInformation>Copyright © 2021 Elsevier Ltd. All rights reserved.</CopyrightInformation>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Baldez</LastName>
            <ForeName>Daniel Prates</ForeName>
            <Initials>DP</Initials>
            <AffiliationInfo>
              <Affiliation>Laboratory of Molecular Psychiatry, Hospital de Clínicas de Porto Alegre, Rua Ramiro Barcelos, 2350, Prédio Anexo, Porto Alegre, 90035-903, Brazil; Programa de Pós-Graduação em Psiquiatria e Ciências do Comportamento, Universidade Federal do Rio Grande do Sul, Rua Ramiro Barcelos, 2400, Porto Alegre, 90035-003, Brazil.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Biazus</LastName>
            <ForeName>Tais Boeira</ForeName>
            <Initials>TB</Initials>
            <AffiliationInfo>
              <Affiliation>Laboratory of Molecular Psychiatry, Hospital de Clínicas de Porto Alegre, Rua Ramiro Barcelos, 2350, Prédio Anexo, Porto Alegre, 90035-903, Brazil.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Rabelo-da-Ponte</LastName>
            <ForeName>Francisco Diego</ForeName>
            <Initials>FD</Initials>
            <AffiliationInfo>
              <Affiliation>Laboratory of Molecular Psychiatry, Hospital de Clínicas de Porto Alegre, Rua Ramiro Barcelos, 2350, Prédio Anexo, Porto Alegre, 90035-903, Brazil; Programa de Pós-Graduação em Psiquiatria e Ciências do Comportamento, Universidade Federal do Rio Grande do Sul, Rua Ramiro Barcelos, 2400, Porto Alegre, 90035-003, Brazil.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Nogaro</LastName>
            <ForeName>Guilherme Pedro</ForeName>
            <Initials>GP</Initials>
            <AffiliationInfo>
              <Affiliation>Laboratory of Molecular Psychiatry, Hospital de Clínicas de Porto Alegre, Rua Ramiro Barcelos, 2350, Prédio Anexo, Porto Alegre, 90035-903, Brazil.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Martins</LastName>
            <ForeName>Dayane Santos</ForeName>
            <Initials>DS</Initials>
            <AffiliationInfo>
              <Affiliation>Laboratory of Molecular Psychiatry, Hospital de Clínicas de Porto Alegre, Rua Ramiro Barcelos, 2350, Prédio Anexo, Porto Alegre, 90035-903, Brazil; Programa de Pós-Graduação em Psiquiatria e Ciências do Comportamento, Universidade Federal do Rio Grande do Sul, Rua Ramiro Barcelos, 2400, Porto Alegre, 90035-003, Brazil.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Kunz</LastName>
            <ForeName>Maurício</ForeName>
            <Initials>M</Initials>
            <AffiliationInfo>
              <Affiliation>Laboratory of Molecular Psychiatry, Hospital de Clínicas de Porto Alegre, Rua Ramiro Barcelos, 2350, Prédio Anexo, Porto Alegre, 90035-903, Brazil; Programa de Pós-Graduação em Psiquiatria e Ciências do Comportamento, Universidade Federal do Rio Grande do Sul, Rua Ramiro Barcelos, 2400, Porto Alegre, 90035-003, Brazil.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Czepielewski</LastName>
            <ForeName>Letícia Sanguinetti</ForeName>
            <Initials>LS</Initials>
            <AffiliationInfo>
              <Affiliation>Laboratory of Molecular Psychiatry, Hospital de Clínicas de Porto Alegre, Rua Ramiro Barcelos, 2350, Prédio Anexo, Porto Alegre, 90035-903, Brazil; Programa de Pós-Graduação em Psicologia, Instituto de Psicologia, Universidade Federal do Rio Grande do Sul, Rua Ramiro Barcelos, 2600, Porto Alegre, 90035-003, Brazil. Electronic address: leticia.czepielewski@ufrgs.br.</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
          <PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
          <PublicationType UI="D016454">Review</PublicationType>
          <PublicationType UI="D000078182">Systematic Review</PublicationType>
        </PublicationTypeList>
        <ArticleDate DateType="Electronic">
          <Year>2021</Year>
          <Month>04</Month>
          <Day>01</Day>
        </ArticleDate>
      </Article>
      <MedlineJournalInfo>
        <Country>United States</Country>
        <MedlineTA>Neurosci Biobehav Rev</MedlineTA>
        <NlmUniqueID>7806090</NlmUniqueID>
        <ISSNLinking>0149-7634</ISSNLinking>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D014150">Antipsychotic Agents</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>12794-10-4</RegistryNumber>
          <NameOfSubstance UI="D001569">Benzodiazepines</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D014150" MajorTopicYN="Y">Antipsychotic Agents</DescriptorName>
          <QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D001569" MajorTopicYN="N">Benzodiazepines</DescriptorName>
          <QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D003071" MajorTopicYN="N">Cognition</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000071076" MajorTopicYN="N">Network Meta-Analysis</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D011618" MajorTopicYN="Y">Psychotic Disorders</DescriptorName>
          <QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D016032" MajorTopicYN="N">Randomized Controlled Trials as Topic</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D012559" MajorTopicYN="Y">Schizophrenia</DescriptorName>
          <QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName>
        </MeshHeading>
      </MeshHeadingList>
      <KeywordList Owner="NOTNLM">
        <Keyword MajorTopicYN="Y">Antipsychotic</Keyword>
        <Keyword MajorTopicYN="Y">Cognition</Keyword>
        <Keyword MajorTopicYN="Y">Network meta-analysis</Keyword>
        <Keyword MajorTopicYN="Y">Psychosis</Keyword>
        <Keyword MajorTopicYN="Y">Randomized controlled trial</Keyword>
        <Keyword MajorTopicYN="Y">Schizophrenia</Keyword>
      </KeywordList>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="received">
          <Year>2020</Year>
          <Month>10</Month>
          <Day>15</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="revised">
          <Year>2021</Year>
          <Month>3</Month>
          <Day>28</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="accepted">
          <Year>2021</Year>
          <Month>3</Month>
          <Day>29</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2021</Year>
          <Month>4</Month>
          <Day>5</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2021</Year>
          <Month>6</Month>
          <Day>29</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2021</Year>
          <Month>4</Month>
          <Day>4</Day>
          <Hour>20</Hour>
          <Minute>40</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>ppublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">33812977</ArticleId>
        <ArticleId IdType="doi">10.1016/j.neubiorev.2021.03.028</ArticleId>
        <ArticleId IdType="pii">S0149-7634(21)00145-7</ArticleId>
      </ArticleIdList>
    </PubmedData>
  </PubmedArticle>
</PubmedArticleSet>
